Europ CPMP Plenary Meeting In May

2 June 1996

The Committee for Proprietary Medicines' sixteenth plenary meeting on May 21-23 adopted six positive opinions (five Part A and one Part B) for five new active substances to be forwarded to the European Commission.

21 positive opinions have now been adopted by concensus since May 1995 (nine new centralized and 12 ex-concertation procedures), and nine European marketing authorizations have been granted; European Public Assessment Reports are available for them. Also at the meeting:

- three new applications were assigned to Rapporteurs and Co-Rapporteurs under the centralized procedure (two Part A and one Part B);

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight